Barclays Issues Positive Forecast for Omada Health (NASDAQ:OMDA) Stock Price

08 May 2026, 12:36 by Doug Wharley · The Cerbat Gem

Omada Health (NASDAQ:OMDA – Get Free Report) had its price objective raised by equities research analysts at Barclays from $18.00 to $20.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Barclays‘s price objective suggests a potential upside of 30.89% from the company’s previous close.

A number of other equities analysts also recently commented on OMDA. Evercore restated an “outperform” rating and issued a $20.00 price objective on shares of Omada Health in a report on Friday. Citigroup restated an “outperform” rating on shares of Omada Health in a research note on Friday. Needham & Company LLC reiterated a “buy” rating and issued a $28.00 price objective on shares of Omada Health in a report on Friday. Citizens Jmp increased their target price on shares of Omada Health from $18.00 to $21.00 and gave the stock a “market outperform” rating in a research report on Friday. Finally, JPMorgan Chase & Co. reduced their price target on Omada Health from $32.00 to $26.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Ten analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $22.91.

Get Our Latest Research Report on OMDA

Omada Health Price Performance

Omada Health stock traded down $1.12 during trading hours on Friday, hitting $15.28. The company had a trading volume of 715,752 shares, compared to its average volume of 1,212,483. Omada Health has a fifty-two week low of $10.28 and a fifty-two week high of $28.40. The firm has a market capitalization of $907.94 million and a P/E ratio of -89.82. The firm’s fifty day moving average is $13.55 and its 200-day moving average is $15.85.

Omada Health (NASDAQ:OMDA – Get Free Report) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03. The company had revenue of $78.05 million during the quarter. Analysts anticipate that Omada Health will post -0.04 earnings per share for the current year.

Insider Buying and Selling at Omada Health

In related news, CEO Sean P. Duffy sold 4,063 shares of the stock in a transaction that occurred on Monday, March 9th. The shares were sold at an average price of $14.34, for a total value of $58,263.42. Following the sale, the chief executive officer directly owned 117,598 shares in the company, valued at $1,686,355.32. This trade represents a 3.34% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, President Wei-Li Shao sold 2,829 shares of the firm’s stock in a transaction on Wednesday, April 8th. The stock was sold at an average price of $12.71, for a total transaction of $35,956.59. Following the sale, the president owned 328,850 shares in the company, valued at approximately $4,179,683.50. The trade was a 0.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders have sold 8,776 shares of company stock valued at $120,483.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in the stock. Geode Capital Management LLC bought a new stake in Omada Health during the second quarter worth $637,000. Walleye Capital LLC bought a new stake in Omada Health in the 2nd quarter valued at $458,000. Ilex Capital Partners UK LLP bought a new position in Omada Health during the second quarter worth $201,000. Soros Fund Management LLC acquired a new position in shares of Omada Health in the second quarter valued at approximately $640,000. Finally, Raymond James Financial Inc. bought a new position in shares of Omada Health during the second quarter worth approximately $32,000.

Key Omada Health News

Here are the key news stories impacting Omada Health this week:

Positive Sentiment: Needham reaffirmed a Buy rating and kept a $28.00 price target (~71% upside vs. the recent price), which supports stronger upside expectations for OMDA. Needham Reaffirms Buy ($28 PT)
Positive Sentiment: Wells Fargo raised its price target to $18.00 and maintained an “Equal Weight” rating, implying modest upside and adding analyst support to the stock. Wells Fargo Raises PT to $18
Positive Sentiment: Q1 results beat consensus: OMDA reported ($0.05) EPS vs. ($0.08) expected and revenue of $78.05M. The upside to EPS and topline gives short‑term confidence that growth is tracking to plan. Q1 Press Release
Positive Sentiment: Management set FY‑2026 revenue guidance of $322.0M–$330.0M versus consensus ~$319.1M, indicating modestly higher revenue expectations for the year. That guidance beat is likely supporting the stock move. FY2026 Guidance (Press Release)
Positive Sentiment: Commercial partnership: Omada will serve as an independent program administrator in Eli Lilly’s Employer Connect program to offer its GLP‑1 Care Track — a distribution channel that could drive membership and medication management revenue. Omada Joins Lilly Employer Connect
Neutral Sentiment: Earnings call transcript and analysis are available for more detail on unit economics, membership trends and margin drivers — useful for investors who want to vet management’s commentary on growth and monetization. Q1 2026 Earnings Call Transcript
Neutral Sentiment: Third‑party coverage (Zacks, Markets Insider/MSN) provides metric-level comparisons to estimates and quarter context; these summaries may influence sentiment but contain no new company-guided data beyond the release. Zacks Q1 Metrics Review

Omada Health Company Profile

(Get Free Report)

Omada Health is a digital health company that specializes in the prevention and management of chronic conditions through personalized, technology-driven programs. The company’s platform combines data analytics, behavioral science and human coaching to support individuals at risk for or living with conditions such as prediabetes, type 2 diabetes, hypertension and musculoskeletal disorders. Participants access the program via a mobile app or web portal, where they receive tailored curriculum, feedback on health metrics and ongoing virtual coaching.